ATE546133T1 - Orale dosierform mit trisubstituierten glycerin- verbindungen - Google Patents
Orale dosierform mit trisubstituierten glycerin- verbindungenInfo
- Publication number
- ATE546133T1 ATE546133T1 AT07822468T AT07822468T ATE546133T1 AT E546133 T1 ATE546133 T1 AT E546133T1 AT 07822468 T AT07822468 T AT 07822468T AT 07822468 T AT07822468 T AT 07822468T AT E546133 T1 ATE546133 T1 AT E546133T1
- Authority
- AT
- Austria
- Prior art keywords
- tris
- dosage form
- oral dosage
- glycerin compounds
- substituted glycerin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85815706P | 2006-11-10 | 2006-11-10 | |
PCT/EP2007/062180 WO2008055996A1 (en) | 2006-11-10 | 2007-11-09 | Oral dosage form comprising tri-substituted glycerol compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE546133T1 true ATE546133T1 (de) | 2012-03-15 |
Family
ID=39092201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07822468T ATE546133T1 (de) | 2006-11-10 | 2007-11-09 | Orale dosierform mit trisubstituierten glycerin- verbindungen |
Country Status (11)
Country | Link |
---|---|
US (2) | US20110110984A1 (de) |
EP (1) | EP2091520B1 (de) |
JP (1) | JP5352466B2 (de) |
CN (2) | CN103816127A (de) |
AT (1) | ATE546133T1 (de) |
AU (1) | AU2007316588B2 (de) |
CA (1) | CA2668919C (de) |
DK (1) | DK2091520T3 (de) |
ES (1) | ES2382756T3 (de) |
RU (1) | RU2009121838A (de) |
WO (1) | WO2008055996A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1745788A1 (de) * | 2005-07-22 | 2007-01-24 | KTB Tumorforschungsgesellschaft mbH | Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie |
AU2007334775A1 (en) * | 2006-12-20 | 2008-06-26 | Universitatsklinikum Hamburg-Eppendorf | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
EP1952803A1 (de) * | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Feste pharmazeutische Darreichungsform mit hydrierten Phospholipiden |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2619686C2 (de) | 1976-05-04 | 1986-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Verwendung eines Lysolecithins zur Tumorbehandlung |
DE3530767A1 (de) * | 1985-08-28 | 1987-03-12 | Max Planck Gesellschaft | Mittel gegen multiple sklerose |
DE3827974A1 (de) * | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen |
DE3918082A1 (de) | 1989-06-02 | 1991-01-24 | Max Planck Gesellschaft | Mittel gegen autoimmunerkrankungen |
DE4000084A1 (de) | 1990-01-03 | 1991-07-04 | Medmark Pharma Gmbh | Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts) |
WO1999030690A1 (en) * | 1997-12-15 | 1999-06-24 | Axia Therapeutics, Inc. | Oral delivery formulation |
DE19822509A1 (de) * | 1998-05-19 | 1999-11-25 | Medmark Pharma Gmbh | Edelfosin zur Behandlung von Hirntumoren |
DE19829448A1 (de) | 1998-07-01 | 2000-10-12 | Medmark Pharma Gmbh | 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen |
ATE290384T1 (de) * | 1998-12-21 | 2005-03-15 | Inkeysa Sa | Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen |
BR0307516A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida |
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
-
2007
- 2007-11-09 CN CN201310689824.XA patent/CN103816127A/zh active Pending
- 2007-11-09 WO PCT/EP2007/062180 patent/WO2008055996A1/en active Application Filing
- 2007-11-09 CN CNA2007800417728A patent/CN101610758A/zh active Pending
- 2007-11-09 DK DK07822468.0T patent/DK2091520T3/da active
- 2007-11-09 AT AT07822468T patent/ATE546133T1/de active
- 2007-11-09 US US12/514,390 patent/US20110110984A1/en not_active Abandoned
- 2007-11-09 JP JP2009535750A patent/JP5352466B2/ja not_active Expired - Fee Related
- 2007-11-09 RU RU2009121838/15A patent/RU2009121838A/ru unknown
- 2007-11-09 EP EP07822468A patent/EP2091520B1/de not_active Not-in-force
- 2007-11-09 AU AU2007316588A patent/AU2007316588B2/en not_active Ceased
- 2007-11-09 ES ES07822468T patent/ES2382756T3/es active Active
- 2007-11-09 CA CA2668919A patent/CA2668919C/en not_active Expired - Fee Related
-
2017
- 2017-02-22 US US15/439,443 patent/US20170157150A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110110984A1 (en) | 2011-05-12 |
CA2668919A1 (en) | 2008-05-15 |
JP5352466B2 (ja) | 2013-11-27 |
EP2091520A1 (de) | 2009-08-26 |
CA2668919C (en) | 2015-11-03 |
WO2008055996A1 (en) | 2008-05-15 |
RU2009121838A (ru) | 2010-12-20 |
ES2382756T3 (es) | 2012-06-13 |
US20170157150A1 (en) | 2017-06-08 |
CN103816127A (zh) | 2014-05-28 |
CN101610758A (zh) | 2009-12-23 |
DK2091520T3 (da) | 2012-06-18 |
EP2091520B1 (de) | 2012-02-22 |
AU2007316588A1 (en) | 2008-05-15 |
JP2010509293A (ja) | 2010-03-25 |
AU2007316588B2 (en) | 2013-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
EA201290026A1 (ru) | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) | |
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
EA201100032A1 (ru) | Соединения пиридина | |
UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
MX2009006764A (es) | Pirimidinonas biciclicas y usos de la misma. | |
NZ714963A (en) | Compositions and methods for treating anemia | |
UA110012C2 (uk) | Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну | |
EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
ATE546133T1 (de) | Orale dosierform mit trisubstituierten glycerin- verbindungen | |
CY1113140T1 (el) | Στερεα μορφη δοσης απο του στοματος, που περιεχει τον αντιαιμοπεταλιακο παραγοντα κλοπιδογρελη, και μεθοδος για την παρασκευη αυτης | |
RU2018130097A (ru) | Лечение экземы кистей | |
ATE474558T1 (de) | Pharmazeutische formulierungen mit irbesartan |